EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study

Nazlı Dilek Çolak, Turgut Karabağ, Onuralp Çalışkan, Songül Tezcan

Journal of the Saudi Heart Association · 20.02.2026 · 38 (1)

DOI: 10.37616/2212-5043.1478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 20.02.2026. Verfasst von Nazlı Dilek Çolak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy, Marmara University, Institute of Health Sciences, 34854, Istanbul, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Carbohydrate antigen 125 (CA125) is associated with different cardiovascular conditions. This study aimed to determine CA125 levels in patients with acute coronary syndrome (ACS) and the potential relationship between major adverse cardiac events (MACE) in the short-term following.

Methods

This prospective cohort study was conducted in a coronary care unit between May and November 2022. Plasma CA125 levels were measured only once upon hospital admission. Patients were followed for six months. All-cause mortality, recurrent acute coronary syndrome, requirement for revascularization, decompensated heart failure, cardiogenic pulmonary edema, atrial fibrillation, and stroke were recorded as MACE.

Results

A total of 127 patients were included in this study. The mean left ventricular ejection fraction (LVEF) was 50.5%. The median plasma CA125 level was 14.6 KU/L. There was a, significant positive relationship between CA125 and high-sensitivity cardiac troponin (hs-cTn) (r = 0.315, p < 0.001) and pro–B-type natriuretic peptide (proBNP) (r = 0.423, p < 0.001), and a weak negative relationship with LVEF (r= −0.186, p = 0.037) value.

Conclusions

Plasma CA125 levels were correlated with the pro-BNP and hs-cTn, established ACS biomarkers. An additional notable finding was the weak correlation with LVEF. Elevated plasma CA125 levels might be used to identify patients with ACS who are at higher risk of MACE at six months.

Schlagwörter

Stichwörter der Autor:innen

Acute coronary syndromeBiomarkerCarbohydrate antigen 125Cardiovascular diseasesMajor cardiac adverse events

Autor:innen und Institutionen

  • Clinical Pharmacy, Marmara University, Institute of Health Sciences, 34854, Istanbul, Turkey.
  • Cardiology, University of Health Sciences, Istanbul Teaching and Research Hospital, 34098, Istanbul, Turkey.
  • Emergency Medicine, Istinye University, Hospital Medical Park Gaziosmanpasa, 34250, Istanbul, Turkey.
  • Clinical Pharmacy, Marmara University, 34854, Istanbul, Turkey.

Zitieren

APA

Çolak, N. D., Karabağ, T., Çalışkan, O., & Tezcan, S. (2026). Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study. Journal of the Saudi Heart Association, 38(1). https://doi.org/10.37616/2212-5043.1478

Vancouver

Çolak ND, Karabağ T, Çalışkan O, Tezcan S. Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study. Journal of the Saudi Heart Association. 2026;38(1). doi:10.37616/2212-5043.1478

BibTeX
@article{olak2026,
  author = {Çolak, Nazlı Dilek and Karabağ, Turgut and Çalışkan, Onuralp and Tezcan, Songül},
  title = {Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Patients With Acute Coronary Syndrome: A Six-Month Follow-Up Study},
  journal = {Journal of the Saudi Heart Association},
  year = {2026},
  volume = {38},
  number = {1},
  doi = {10.37616/2212-5043.1478}
}
Kostenlos starten →